1. Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis of Randomized Controlled Trials 
Lan Gao, PhD, Fei-Li Zhao, PhD, MPH, Shu-Chuen Li, PhD, MBA 
Value in Health Regional Issues 
Volume 6, Pages (May 2015)
DOI: /j.vhri
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1 Study selection process. RCT, randomized controlled trial.
Value in Health Regional Issues 2015 6, 22-32DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Pooled efficacy effects (TRA vs placebo) for patients with ACS. ACS, acute coronary syndrome; CI, confidence interval; CV, cardiovascular; MACE, major adverse cardiovascular event; MI, myocardial infarction; TRA, thrombin-receptor antagonist.
Value in Health Regional Issues 2015 6, 22-32DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Pooled safety effects (TRA vs placebo) for patients with ACS. ACS, acute coronary syndrome; CI, confidence interval; TIMI, thrombolysis in myocardial infarction; TRA, thrombin-receptor antagonist.
Value in Health Regional Issues 2015 6, 22-32DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Pooled efficacy effects (TRA vs placebo) for patients with CAD. CAD, coronary artery disease; CI, confidence interval; CV, cardiovascular; MACE, major adverse cardiovascular event; MI, myocardial infarction; TRA, thrombin-receptor antagonist.
Value in Health Regional Issues 2015 6, 22-32DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

6. Fig. 5
Pooled safety effects (TRA vs placebo) for patients with CAD. CAD, coronary artery disease; CI, confidence interval; TIMI, thrombolysis in myocardial infarction; TRA, thrombin-receptor antagonist.
Value in Health Regional Issues 2015 6, 22-32DOI: ( /j.vhri )
Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions